Li S, Anwar I, Canning A, Vo-Dinh T, Kirk A, Xu H
Am J Transplant. 2023; 23(7):904-919.
PMID: 37054891
PMC: 10330644.
DOI: 10.1016/j.ajt.2023.04.006.
Sikorska D, Kaminska D, Catar R, Banasik M, Heidecke H, Schulze-Forster K
J Clin Med. 2022; 11(3).
PMID: 35160284
PMC: 8837026.
DOI: 10.3390/jcm11030833.
Peelen D, Hoogduijn M, Hesselink D, Baan C
Front Immunol. 2021; 12:607953.
PMID: 33664744
PMC: 7921837.
DOI: 10.3389/fimmu.2021.607953.
Uehara M, Bahmani B, Jiang L, Jung S, Banouni N, Kasinath V
ACS Nano. 2019; 13(11):12393-12407.
PMID: 31518498
PMC: 7247279.
DOI: 10.1021/acsnano.9b05115.
Win T, Murakami N, Borges T, Chandraker A, Murphy G, Lian C
JCI Insight. 2017; 2(13).
PMID: 28679959
PMC: 5499367.
DOI: 10.1172/jci.insight.93894.
Underlying Mechanisms of Protection Involved in Immunocloak.
Brasile L, Henry N, Stubenitsky B
Transplantation. 2016; 101(2):e49-e56.
PMID: 27764033
PMC: 5837069.
DOI: 10.1097/TP.0000000000001537.
Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching.
Schlaf G, Pollok-Kopp B, Manzke T, Schurat O, Altermann W
NDT Plus. 2015; 3(6):527-38.
PMID: 25949460
PMC: 4421419.
DOI: 10.1093/ndtplus/sfq156.
Novel CD8 T cell alloreactivities in CCR5-deficient recipients of class II MHC disparate kidney grafts.
Ishii D, Rosenblum J, Nozaki T, Schenk A, Setoguchi K, Su C
J Immunol. 2014; 193(7):3816-24.
PMID: 25172484
PMC: 4170018.
DOI: 10.4049/jimmunol.1303256.
Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.
Schlaf G, Pollok-Kopp B, Altermann W
Mol Diagn Ther. 2013; 18(2):185-201.
PMID: 24170304
DOI: 10.1007/s40291-013-0063-2.
Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro.
Samsonov D, Geehan C, Woda C, Briscoe D
Transplant Res. 2013; 1(1):4.
PMID: 23369287
PMC: 3552572.
DOI: 10.1186/2047-1440-1-4.
VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.
Daly K, Seifert M, Chandraker A, Zurakowski D, Nohria A, Givertz M
J Heart Lung Transplant. 2012; 32(1):120-8.
PMID: 23260712
PMC: 3597743.
DOI: 10.1016/j.healun.2012.09.030.
Targeting the intragraft microenvironment and the development of chronic allograft rejection.
Dormond O, Dufour M, Seto T, Bruneau S, Briscoe D
Hum Immunol. 2012; 73(12):1261-8.
PMID: 22863981
PMC: 3496805.
DOI: 10.1016/j.humimm.2012.07.334.
Innate immunity and resistance to tolerogenesis in allotransplantation.
Benichou G, Tonsho M, Tocco G, Nadazdin O, Madsen J
Front Immunol. 2012; 3:73.
PMID: 22566954
PMC: 3342343.
DOI: 10.3389/fimmu.2012.00073.
Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation.
Bruneau S, Woda C, Daly K, Boneschansker L, Jain N, Kochupurakkal N
Front Immunol. 2012; 3:54.
PMID: 22566935
PMC: 3342046.
DOI: 10.3389/fimmu.2012.00054.
[The role of endothelial cells in allograft rejection].
Regele H
Pathologe. 2008; 29 Suppl 2:141-4.
PMID: 18820919
DOI: 10.1007/s00292-008-1077-0.
Heat shock protein 70, heat shock protein 32, and vascular endothelial growth factor production and their effects on lipopolysaccharide-induced apoptosis in porcine aortic endothelial cells.
Bernardini C, Zannoni A, Turba M, Fantinati P, Tamanini C, Bacci M
Cell Stress Chaperones. 2005; 10(4):340-8.
PMID: 16333987
PMC: 1283877.
DOI: 10.1379/csc-98r1.1.
Human leukocyte antigen antibodies for monitoring transplant patients.
Cai J, Terasaki P
Surg Today. 2005; 35(8):605-12.
PMID: 16034537
DOI: 10.1007/s00595-005-3015-6.